Analysis of retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data
Farmacia Hospitalaria · 2024
DOI: 10.1016/j.farma.2024.02.003 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Farmacia Hospitalaria, 2024. Verfasst von Patricia García-Lloret und 3 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Farmacia, Hospital de Valme, Sevilla, Spain. Electronic address: patricia.garcia.lloret.sspa@juntadeandalucia.es. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Retreatment. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVE: To analyze the response to retreatment in patients with chronic/episodic migraine who discontinued therapy with erenumab/fremanezumab after 1 year of treatment. METHODS: Observational, retrospective, single-center, multidisciplinary study in patients with chronic/episodic migraine who received therapy with erenumab/fremanezumab for at least 1 year and discontinued it after achieving an adequate response (optimization). The evaluation of the response after retreatment included the following variables: DMM, MIDAS, and HIT-6 scales at the beginning of retreatment and 3 months later. The response was evaluated in different subgroups (episodic/chronic, erenumab/fremanezumab, and time until retreatment). RESULTS: 48 patients were included. 70.8% (n=34) required retreatment with mAb, with a median of 3.9 (2.9-6.4) months until reintroduction. Clinical response after retreatment was achieved in 67.6% (n=23) of patients. No statistically significant differences were found in the analyzed subgroups. CONCLUSION: Interruption of treatment with erenumab/fremanezumab for chronic/episodic migraine produces a clinical worsening of the disease requiring retreatment in most cases, approximately after 4 months. Two out of three patients respond positively after restarting monoclonal therapy. This response does not appear to be related to the type of migraine, the specific monoclonal antibody prescribed, or the time to retreatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Farmacia, Hospital de Valme, Sevilla, Spain. Electronic address: patricia.garcia.lloret.sspa@juntadeandalucia.es.
- Servicio de Farmacia, Hospital de Valme, Sevilla, Spain.
- Servicio de Neurología, Hospital de Valme, Sevilla, Spain.
Zitieren
APA
García-Lloret, P., Galván-Banqueri, M., Robustillo-Cortés, M. L. A., & Fernández-Recio, M. (2024). Analysis of retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2024.02.003
Vancouver
García-Lloret P, Galván-Banqueri M, Robustillo-Cortés MLA, Fernández-Recio M. Analysis of retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data. Farmacia Hospitalaria. 2024. doi:10.1016/j.farma.2024.02.003
BibTeX
@article{GarcaLloret2024,
author = {García-Lloret, Patricia and Galván-Banqueri, Mercedes and Robustillo-Cortés, María de Las Aguas and Fernández-Recio, María},
title = {Analysis of retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data},
journal = {Farmacia Hospitalaria},
year = {2024},
doi = {10.1016/j.farma.2024.02.003}
}
EUVIMED